Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +1353.76% | +362.03% | +210.77% |
| Gross Profit Growth | +0.00% | +0.00% | +1355.06% | +348.40% | +197.01% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +10.97% | +10.45% | +3.76% | +3.39% | +2.30% |
| Weighted Average Shares Diluted Growth | +10.97% | +10.45% | +3.76% | +3.39% | +2.30% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +1048.44% | +271.88% | +149.85% |
| Inventory Growth | +0.00% | +6368.50% | +797.86% | +695.38% | +119.68% |
| Asset Growth | +62.71% | -7.91% | -7.67% | +26.95% | +20.85% |
| Book Value per Share Growth | +67.71% | -24.37% | -21.74% | -22.12% | -21.91% |
| Debt Growth | +2.03% | +1.74% | +4.98% | +190.75% | +196.36% |
| R&D Expense Growth | -63.69% | -37.99% | -23.93% | +153.13% | +353.32% |
| SG&A Expenses Growth | +203.47% | +107.77% | +86.69% | +94.37% | +69.93% |